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Mitochondrial dysfunction named complex I syndrome was observed in striatum 
mitochondria of rotenone treated rats (2 mg rotenone/kg, i.p., for 30 or 60 days) in an 
animal model of Parkinson disease. After 60 days of rotenone treatment, the animals 
showed: (a) 6-fold increased bradykinesia and 60% decreased locomotor activity; (b) 
35-34% decreases in striatum O2 uptake and in state 3 mitochondrial respiration with 
malate-glutamate as substrate; (c) 43-57% diminished striatum complex I activity with 
60-71% decreased striatum mitochondrial NOS activity, determined both as biochemical 
activity and as functional activity (by the NO inhibition of active respiration); (d) 34-40% 
increased rates of mitochondrial O2
•- and H2O2 productions and 36-46% increased 
contents of the products of phospholipid peroxidation and of protein oxidation; and (e) 24% 
decreased striatum mitochondrial content, likely associated to decreased NO-dependent 
mitochondrial biogenesis. Intermediate values were observed after 30 days of rotenone 
treatment. Frontal cortex tissue and mitochondria showed similar but less marked 
changes. Rotenone-treated rats showed mitochondrial complex I syndrome associated 
with cellular oxidative stress in the dopaminergic brain areas of striatum and frontal cortex, 






























L-NAME: NG-nitro-L-arginine methyl ester 
L-NMMA: NG-methyl-L-arginine 
NOS: nitric oxide synthase 
nNOS: neuronal nitric oxide synthase 
mtNOS: mitochondrial nitric oxide synthase 





















Human brain requires a continuous energy supply that is expressed by brain O2 
consumption which accounts for 20% of the total O2 taken up in spite that brain weight is 
only 2% of total body mass [1]. Mitochondrial complex I (NADH-ubiquinone reductase) is a 
large protein complex that transfers electrons from NADH to ubiquinone with the 
simultaneous pumping of H+ from the mitochondrial matrix to the intermembrane space   
[2-4], an essential activity in the chemiosmotic mechanism of oxidative phosphorylation. 
The mitochondrial dysfunction with altered complex I activity has been named “complex I 
syndrome” [5], characterized by (a) decreases in tissue and mitochondrial O2 
consumptions, this latter observed only with NAD-dependent substrates; (b) reduction in 
complex I and in nitric oxide synthase (mtNOS) activities; and (c) increases in the rates of 
mitochondrial superoxide anion (O2
•-) and hydrogen peroxide (H2O2) production and in the 
contents of lipid peroxidation and protein oxidation products. It is understood that 
complex I syndrome describes the high sensitivity of mitochondrial complex I to 
inactivation by oxidative reactions. The mentioned mtNOS is the mitochondrial form of 
NOS, originally reported in rat liver mitochondria by Giulivi et al. [6-8] and later identified as 
the shorter α-variant of nNOS by Elfering et al. [9]. Mitochondrial NOS seems to be 
contiguously located to complex I being both enzymes functionally linked [10-13]. Particles 
from heart mitochondria produce NO by succinate-dependent reverse electron flow [13]. 
The association between mtNOS and complex I is compatible with the concept of 
respiratory chain supercomplexes with strong protein-protein interactions [14], and with the 
dependence of mtNOS activity on the metabolic states and on membrane potential [15,16].  
Complex I dysfunction has been observed in Parkinson’s disease [17,18], ischemia-
reperfusion [12,19], endotoxic shock [20] and aging [21-23], accompanied by changes in 
mtNOS activity [12, 18-21]. In rat brain, mitochondrial NO production has been reported in 
cortex, hippocampus and striatum [24-26]. Nitric oxide is deeply involved in brain 
physiology and biochemistry by the NO-cGMP-dependent vasodilation [27], and by the 

















for NO within the brain include promotion of mitochondrial biogenesis and regulation of 
calcium channels function [30,31]. 
Human Parkinson disease (PD) is a neurodegenerative disorder with clinical signs of 
neuromotor impairment: bradykinesia, rest tremor, muscular rigidity and a flexed posture 
[32,33]. The occurrence of motor and non-motor symptoms in PD raised the interest on the 
mitochondrial function in the involved dopaminergic brain areas. Striatum bodies, in short 
striatum, are bilateral areas of coordination and integration of involuntary movements 
located in the main pathway of motor impulses. Striatum has efferent connections to 
substantia nigra and to other midbrain nuclei [33] involved in processing emotions and in 
performing cognitive and psychological associations [34].  
Animal models of PD have contributed to the knowledge of the biochemical and 
cellular characteristics of the disease. These models use toxins targeted to dopaminergic 
neurons and reproduce the motor symptoms of human PD [35-39]. Between those toxin, 
rotenone, is hydrophobic, accumulates in mitochondria and inhibits mitochondrial 
respiration. Therefore, this report deals with the mitochondrial function in striatum and in 
frontal cortex of rats chronically treated with rotenone. The two mentioned brain areas 
show “complex I syndrome” and oxidative stress, two conditions that seem to be involved 


















MATERIALS AND METHODS 
 
1. Drugs and chemicals 
Rotenone and chemicals were purchased from Sigma Chemical Co. (St. Louis, MO, 
USA). Other reagents were of analytical grade. 
 
2. Experimental design 
2.1. Animals 
Male Wistar rats (270 ± 12 g, 3 months old) from the Department of Experimental 
Animals of the University of Cadiz were housed at 22 ± 1 °C, with 12 h light/dark cycles, 
and with full access to water and food. Experiments were carried out in accordance with 
the Guiding Principles for Research Involving Animals of the American Physiological 
Society, the Guidelines of the European Union Council (86/609/CEE), and the Spanish 
regulations for the use of laboratory animals (BOE 67/8509-12, 1988). 
 
2.2. Rotenone treatment  
Rotenone injections (2.0 mg/kg rat, i.p., 6 days a week) were given for 30 or 60 days 
as described by Alam and Schmidt [37,38]. Rats were randomized into 3 groups of 15 rats 
each: control, 30 days-rotenone, and 60 days-rotenone. Animals were weighed prior to 
injection.  Control rats were injected with vehicle (olive oil).  
 
3. Neurologic and locomotive tests 
The tests of catalepsy and of open field activity were performed weekly. In the 
catalepsy test, aimed to evaluate bradykinesia and rigidity, each rat was hung by the paws 
on a vertical grid (25 cm wide and 45 cm high with 1 cm between wires). The time taken to 
move one of the paws was determined. The open-field test was used to assess the 

















walls. The frequency which rats stood up on their hind legs and the total standing time 
during 10 min were recorded [37].  
 
4. Isolation of striatum and frontal cortex mitocho ndria 
Rats were killed by decapitation, brain was quickly removed after opening the skull 
and striatum and frontal cortex were immediately excised [24,40]. Striatum and frontal 
cortex from 5 rats were pooled for mitochondrial isolation, that was performed as described 
[24,41]. Tissue fragments were washed and homogenized in 230 mM mannitol, 70 mM 
sucrose, 1.0 mM EDTA and 10 mM Tris-HCl, pH 7.40, at 9 ml of homogenization 
medium/g of brain in a small Potter homogenizer with a Teflon pestle. Homogenates were 
centrifuged at 700g for 10 min, the pellets were discarded and the supernatants 
centrifuged at 8000g for 10 min to precipitate mitochondria that were washed in the same 
conditions. Mitochondrial suspensions of about 15 mg protein/ml were either rapidly used 
to measure O2 uptake, H2O2 production and mtNOS functional activity or frozen in liquid N2 
and kept at -80 °C for other determinations. Mitochondrial membranes (fragments) were 
obtained from twice frozen and thawed mitochondria homogenized each time by passage 
through a hypodermic needle. Mitochondrial protein was determined by the Folin reagent 
with bovine serum albumin as standard. 
 
5. Tyrosine hydroxylase immunohistochemistry 
Brain transversal sections were washed and incubated with mouse anti-tyrosine 
hydroxylase antibody (MAB5280, 1/1000) for 24 hours. The sections were incubated with 
biotinylated anti-mouse IgG (BA2001; 1/200) and with an antibody forming an avidin-
peroxidase complex for reaction visualization by incubation with diaminobenzidine in 0.3% 
H2O2 [42]. High-resolution photos were obtained with a digital camera in a Nikon 
microscope DXM1200F Optiphot-2 and processed with Image-J software (National 


















6. Tissue and mitochondrial respiration  
6.1. Tissue O 2 uptake 
Striatum and frontal cortex were sectioned into about 1-mm tissue cubes and the O2 
uptake of 4–8 cubes was determined with a Clark electrode (Hansatech Instruments Ltd., 
Norfolk, UK) in a 1.5-ml chamber at 30 °C in air-saturated Krebs medium with 118 mM 
NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 2.5 mM CaCl2, 25 mM NaHCO3, and 
5.5 mM glucose, pH 7.40 [24]. After 1-2 min, tissue O2 uptake, linearly dependent on the 
number of tissue cubes, remained stable and was recorded for 2-3 min. Oxygen uptake 
was expressed in ng-at O/min × g tissue.  
 
6.2. Mitochondrial O 2 uptake 
This was determined with a Clark electrode in a 1.5 ml chamber at 30 °C in an air-
saturated reaction medium consisting of 230 mM mannitol, 70 mM sucrose, 20 mM Tris-
HCl, 1 mM EDTA, 5 mM KH2PO4/K2HPO4, 3 mM MgCl2, pH 7.40, and 0.6-0.8 mg 
protein/ml. Respiration was determined with either 5 mM malate-5 mM glutamate or 10 
mM succinate as substrates. State 3 active respiration was established by addition of 0.50 
mM ADP [41]. Results were expressed as ng-at O/ min × mg protein and the respiratory 
control ratio (RC) was calculated as the ratio of state 3/state 4 respiration rates.  
 
6.3. Biochemical and functional mtNOS activities  
Nitric oxide production by biochemical mtNOS activity was determined by the 
oxyhemoglobin (HbO2) oxidation assay, followed at the HbO2 α-band at 37 °C [43] in a 
modification of the assay described by Ignarro et al. [27]. The HbO2 α-band makes the 
determination in turbid suspensions possible by decreasing light scattering. The reaction 
medium consisted of 0.10 mM NADPH, 1.0 mM L-arginine, 1.0 mM CaCl2, 2.0 µM Cu,Zn-
superoxide dismutase (Cu,Zn-SOD), 0.1 µM catalase and 20 µM HbO2 hem,  50 mM 

















spectrophotometer (8453 Agilent Corp., Palo Alto, CA, USA) was used with 577 nm as 
active wavelength with a reference wavelength at the isosbestic point of 591 nm (ε577-591= 
11.2 mM−1 cm−1). NO production was calculated from the absorbance change inhibited by 
2 mM L-NMMA, usually 92-96%, and expressed in nmol NO/min × mg protein.  
Mitochondrial NOS functional activity was determined by the inhibition of 
mitochondrial O2 consumption by endogenous NO production, as observed by Giulivi [8] 
and described by Valdez et al. [45]. The assay determines the difference between the 
state 3 rates of O2 uptake, at maximal NO steady state concentrations in the presence of 
1.0 mM L-arginine and 1.0 µM Cu,Zn-SOD, and at minimal NO steady state levels in the 
presence of 2.0 mM L-NAME and 20 µM oxyhemoglobin (HbO2).  
 
6.4. Respiratory complexes activities 
The enzymatic activities of complexes I, I-III, II-III, and IV were determined 
spectrophotometrically at 30 °C using mitochondrial membranes [46]. Complex I-III 
(NADH-cytochrome c reductase) and complex II-III (succinate-cytochrome c reductase) 
activities were determined in 100 mM KH2PO4/K2HPO4, pH 7.40, with 0.20 mM NADH or 
5.0 mM succinate as substrates, 0.10 mM cytochrome c3+ and 1.0 mM KCN at 550 nm 
(ε=19 mM-1 cm-1) and expressed as nmol reduced cytochrome c / min × mg protein. 
Complex I activity was also determined as NADH-ferricyanide reductase at 420 nm in the 
same buffer with 0.20 mM NADH, 1 mM K3Fe(CN)6 (ε = 1.0 mM-1 cm-1) and 1 mM KCN 
and expressed as nmol reduced ferricyanide/min × mg protein. Cytochrome oxidase 
(complex IV) was determined at 550 nm in the reaction medium used for complex I with 50 
µM cytochrome c2+, as the pseudo first order reaction constant (k′)/mg protein and 
expressed as nmol oxidized cytochrome c at 20 µM cytochrome c2+, that results in electron 



















7. Reactive oxygen species and protein and lipid ox idation products 
7.1. Superoxide anion and hydrogen peroxide product ion  
The rates of O2
•- and H2O2 production were determined in mitochondrial fragments at 
30 °C [47]. Superoxide radical was determined spectrophotometrically following the 
reduction of 20 µM acetylated cytochrome c3+ at 550-540 nm (ε = 19 mM-1 cm-1) [38]. 
Hydrogen peroxide was determined fluorometrically at 365 nm (excitation) and 450 nm 
(emission) with 0.5 µM horseradish peroxidase and 1.0 µM scopoletin. The reaction 
medium was 230 mM mannitol, 70 mM sucrose, 20 mM Tris-HCl. pH 7.40, with 50 µM 
NADH as substrate and 0.05-0.10 mg protein/ml. For O2
•- determinations, mitochondrial 
fragments were washed three times in 140 mM KCl, 20 mM Tris-HCl, pH 7.40, to eliminate 
endogenous SOD. The specificities for O2
•- and H2O2 reaction were confirmed by 2 µM 
Cu,Zn-SOD or 2 µM catalase that inhibited the assays by 96-98%. SOD-sensitive and 
catalase-sensitive rates were expressed as nmol O2
•- or H2O2/min × mg protein. 
 
7.2. Tissue oxidative damage 
The mitochondrial content of thiobarbituric acid-reactive substances (TBARS) and 
of protein carbonyl groups (>C=O) were determined as described [24,46]. Phospholipid 
peroxidation was expressed in nmol TBARS/mg protein and protein oxidation in nmol 
carbonyl group/mg protein.  
 
8. Cytochrome oxidase activity and cytochrome conte nt  
8.1. Mitochondrial content 
Tissue mitochondrial mass was determined from the ratio of cytochrome oxidase 
activities in homogenates and in mitochondria [24]. Cytochrome oxidase activity was 
determined in 100 mM KH2PO4/K2HPO4, pH 7.40, with 50 µM cytochrome c2+. Cytochrome 
c2+ oxidation by complex IV was calculated as the pseudo-first-order reaction constant (k´) 

















between the activity measured in homogenates (k´/g tissue) and in mitochondrial 
membranes (k´/mg protein) yields the mitochondrial mass per gram of tissue. Reduced 
cytochrome c was freshly prepared by reduction of cytochrome c3+ with Na2S2O4 followed 
by Sephadex G-25 chromatography. 
 
8.2. Mitochondrial cytochrome content 
Cytochromes were determined in a diode array spectrophotometer by scanning 
between 650 and 500 nm the absorption difference between dithionite reduced and 
oxidized samples, at the following wavelengths and extinction coefficients: cytochromes c 
+ c1, 550-540 nm and 19 mM
−1 cm−1; cytochromes bK + bT, 562-575 nm and 22 mM
−1 cm−1; 
cytochromes a + a3, 605-630 nm and 21 mM
−1 cm−1 [49].  
 
9. Statistics 
Values are means ± SEM (n = 3). Striatum and frontal cortex from 5 rats were 
pooled for mitochondrial isolation. Differences were analyzed by one-way ANOVA and by 
Student-Newman-Keuls tests. Values of p<0.05 and p<0.01 were considered significant 



















1. Neurologic and locomotive tests 
After 6 weeks of rotenone treatment, rats showed severe bradykinesia with a marked 
increase (6-fold) in the catalepsy test (Fig. 1A). Similarly, an important decrease (60%) 
was observed in spontaneous locomotive activity in the open field test (Fig. 1B). 
 
 
Figure 1. Effect of rotenone treatment on rat motor activity. (A) catalepsy test, and (B) 
open field spontaneous locomotor activity. Control rats (open circles) and rotenone-treated 


















2. Tyroxine hydroxylase histochemistry 
Transversal brain sections showed a highly decreased tyrosine hydroxylase activity 
in 60 days rotenone-treated rats as compared with control animals (Fig. 2). The affected 
mid-brain area included the nigrostriatal pathway. Decreased tyrosine hydroxylase 
histochemistry indicated a marked cell death with loss of dopaminergic neurons. The loss 
was estimated at about 50% by spectrophotometric determination of film absorbance. 
 
 
Figure 2.  Tyrosine hydroxylase immunohistochemistry of brains from control and 60 days 
rotenone treated rats. 
 
3. Striatum and frontal cortex tissue O 2 consumption 
Striatum and frontal cortex exhibited linear respiratory rates that were decreased 
after 60 days of rotenone treatment by 35 and 10%, respectively, with intermediate values 
at 30 days (Table 1).   
 
Table 1.  Tissue O2 uptake of striatum and frontal cortex in rotenone-treated and control 
rats  
 Oxygen consumption 
(ng at O/min × g tissue) 
Brain tissue  Control Rotenone 
  30 days 60 days 
Striatum 896 ± 24 (100%)  744 ± 21** (83%) 582 ± 20*** (65%) 


















In parenthesis, respiration rates expressed as percentage of control values.      
***p<0.001, **p<0.01, *p<0.05, rotenone-treated versus control rats. 
 
4. Mitochondrial function 
4.1. Mitochondrial O 2 consumption 
Striatum and frontal cortex mitochondria of rotenone-treated rats showed a 
significantly decreased active respiration (state 3, with ATP synthesis) with malate-
glutamate as substrate (Table 2). The inhibitions of O2 uptake in striatum mitochondria 
were 16 % and 34 % after 30 and 60 days of rotenone treatment. Resting (state 4) 
respiration remained unchanged and respiratory control, the ratio state 3/state 4 of O2 
uptakes, declined according to the decreased state 3 respiratory rates. Frontal cortex 
mitochondria exhibited a similar, although less marked, respiratory inhibition that was only 
16 % after 60 days of rotenone treatment.  
In contrast, with succinate as substrate both striatum and frontal cortex state 3 O2 

































Table 2.  Oxygen uptake of striatum and frontal cortex mitochondria from rotenone-treated 
and control rats 
 
 
Oxygen consumption  
(ng-at O/min × mg protein) 
 Control  Rotenone  
  30 days  60 days  
STRIATUM    
Malate-glutamate     
State 3 166 ± 9 (100%) 140 ± 8 (84%) 109 ± 7** (66%) 
State 4 42 ± 3 40 ± 3 38 ± 3 
Respiratory control  3.9 ± 0.3 3.5 ± 0.3 2.0 ± 0.3* 
Succinate     
State 3 220 ± 12 (100%) 210 ± 11 (95%) 199 ± 9 (90%) 
State 4 60 ± 4 58 ± 4 52 ± 4 
Respiratory control  3.7 ± 0.3 3.6 ± 0.3 3.7 ± 0.3 
FRONTAL CORTEX     
Malate-glutamate     
State 3 143 ± 8 (100%) 133 ± 8(93%) 120 ± 7* (84%) 
State 4 27 ± 2 26 ± 2 25 ± 2 
Respiratory control  5.3 ± 0.3 5.1 ± 0.3 4.8 ± 0.4 
Succinate     
State 3 179 ± 9 (100%) 169 ± 9 (94%) 164 ± 3 (92%) 
State 4 44 ± 3 44 ± 3 42 ± 3 
Respiratory control  4.1 ± 0.3 3.8 ± 0.3 3.6 ± 0.3 
 
In parenthesis, state 3 respiration as percentage of control values       




















4.2. Activities of mtNOS and of respiratory complex es  
Striatum mtNOS activity was decreased to 73% and to 40% after 30 and 60 days of 
rotenone treatment (Table 3). Moreover, complex I activity was also diminished to 57-43 % 
after 60 days of treatment, measured as NADH-cytochrome c reductase and as 
NADH-ferricyanide reductase, with intermediate effects after 30 days of treatment. 
Accordingly, similar marked declines of complex I and mtNOS activities were observed in 
striatum mitochondria after rotenone treatment. In addition, complex I activity was 
significantly reduced to 70 % in frontal cortex after 60 days of treatment.  
In contrast, complexes II-III and IV activities were not significantly modified in either 
of the tissues studied. 
 
Table 3. Activities of mtNOS and of respiratory complexes in striatum and frontal cortex 
mitochondria from control and rotenone-treated rats 
 Mitochondrial activities 
 Control Rotenone 
  30 days 60 days 
STRIATUM 
mtNOS 0.48 ± 0.04 (100%) 0.35 ± 0.04   (73%) 0.19 ± 0.03** (40%) 
Complex I 170 ± 11     (100%) 141 ± 10      (83%)  73 ± 6***       (43%) 
Complex I-III 260 ± 12     (100%)  216 ± 12      (83%)  148 ± 10        (57%)  
Complex II-III 119 ± 9       (100%) 117 ± 9        (98%) 115 ± 9          (97%) 
Complex IV 150 ± 12     (100%) 122 ± 10      (81%) 116 ± 10        (77%) 
FRONTAL CORTEX 
mtNOS 0.45 ± 0.04 (100%) 0.44 ± 0.04  (98%) 0.41 ± 0.03    (91%) 
Complex I 207 ± 12    (100%) 200 ± 11      (97%) 145 ± 10*       (70%) 
Complex I-III 309 ± 15    (100%)  303 ± 14      (98%)  278 ± 12         (90%)  
Complex II-III 121 ± 9     (100%) 119 ± 9        (99%) 118 ± 8           (98%) 

















In parenthesis, enzymatic activities expressed as percentages of control values.     
mtNOS activity is given in nmol NO/min × mg protein. Activities of complexes I and II are 
given in nmol reduced cytochrome c/ min × mg protein. Complex IV activity is expressed 
as the pseudo first order constant (k´)/mg protein at 20 µM cytochrome c. 
***p<0.001, **p<0.01, *p<0.05, rotenone-treated versus control rats 
 
4.3. Functional activity of mtNOS in striatum mitoc hondria  
Mitochondrial NOS functional activity was assayed through the inhibition of O2 
consumption produced by NO [45]. State 3 respiratory rates were determined at maximal 
(L-arginine and SOD added) and minimal (L-NAME and HbO2 added) intramitochondrial 
NO concentration. The difference between the state 3 O2 uptake in the presence of 
L-arginine and SOD (a) and in the presence of a NOS inhibitor and HbO2 (b) indicates the 
mtNOS functional activity in the inhibition of cytochrome oxidase activity. Table 4 shows 
that supplementation of control striatum mitochondria with L-arginine and SOD, providing 
the mtNOS substrate and removing extramitochondrial O2
•-, decreased state 3 respiration, 
while the addition of L-NAME and HbO2 to the reaction medium increased O2 uptake. 
Thus, the mtNOS functional activity in control striatum mitochondria accounted for 14% of 
state 3 O2 uptake, and decreased to 71% after 30 days of rotenone treatment and to 29% 
after 60 days of treatment. A remarkable agreement in the inhibitions of mtNOS activity 
determined by the biochemical and by the functional activity assays was observed (Fig. 3). 
Moreover, linear correlations were observed (Fig. 3) between complex I activity and 
mtNOS biochemical and functional activities (r2 = 0.98 and 0.97) and between complex I 
activity and malate-glutamate supported state 3 O2 uptake (r
2 = 0.98), measured in 
striatum mitochondria, indicating that the pattern observed for complex I activity decline is 
associated to mtNOS activity reduction and to the impairment of striatum mitochondrial 


















Table 4. Functional activity of mtNOS in striatum mitochondria from rotenone-treated and 
control rats. 
 Oxygen consumption 
(ng-at O/min × mg protein) 
 Control Rotenone 
  30 days 60 days 
State 3 (malate-glutamate) 166 ± 9 (100%) 140 ± 8 (84%) 109 ± 7 (66%) 
a State 3 + L-arginine + SOD 158 ± 11  133 ± 9  113 ± 8  
b State 3 + L-NAME + HbO2 182 ± 12  150 ± 10   120 ± 9   
b-a mtNOS functional activity  24 ± 2 (100%) 17 ± 2 (71%) 7 ± 2** (29%) 
In parenthesis, percentage of the control values of state 3 respiration and of mtNOS 
functional activity. **p<0.01, rotenone-treated versus control rats 
 
 
Figure 3.  Linear correlations between mitochondrial complex I activity and malate-glutamate 
supported state 3 respiration (●) (r2 = 0.97) and between complex I activity and mtNOS 


















On the other hand, no significant changes were observed in mtNOS functional 
activity in frontal cortex (data not shown), in agreement with no significantly changes 
observed in mtNOS biochemical activity (Table 3) in this brain area. 
 
5. Mitochondrial O 2
•- and H 2O2 production and products of oxidative damage  
The O2
•- and H2O2 production rates of striatum and frontal cortex mitochondria were 
increased (34-44%) after 60 days of rotenone-treatment, with intermediate values at 30 
days (Table 5). The ratios 1.9-2.1 of O2
•- over H2O2 rates respectively, indicate that O2
•-  is 
the stoichiometric precursor of mitochondrial H2O2. 
Phospholipid peroxidation and protein oxidation were increased in striatum and 
frontal cortex mitochondria after 60 days of treatment (Table 5). Phospholipid peroxidation, 
determined as TBARS, increased 28-36%, and protein oxidation, determined as >C=O 































Table 5. Mitochondrial production of O2
•- and of H2O2 and TBARS and protein carbonyls 
contents in striatum and frontal cortex mitochondria of control and rotenone-treated rats  
 Control Rotenone 
  30 days 60 days 
STRIATUM 
O2
•- production 1.50 ± 0.07 1.61 ± 0.07 2.01 ± 0.08** 
H2O2  production 0.70 ± 0.03 0.82 ± 0.04 0.98 ± 0.04** 
Phospholipid peroxidation 1.48 ± 0.05 1.74 ± 0.05* 2.02 ± 0.06*** 
Protein oxidation  26 ± 2 32 ± 3 38 ± 3* 
FRONTAL CORTEX 
O2
•- production 1.17 ± 0.06 1.21 ± 0.06 1.65 ± 0.08** 
H2O2 production 0.57 ± 0.03 0.59 ± 0.03 0.82 ± 0.04** 
Phospholipid peroxidation 1.39 ± 0.05 1.68 ± 0.06* 1.78 ± 0.06** 
Protein oxidation  23 ± 2 26 ± 2 30 ± 2 
 
O2
•- and H2O2 productions are expressed as nmol/min × mg protein; phospholipid 
peroxidation as nmol TBARS/mg protein; and protein oxidation as nmol carbonyl group/ 
mg protein. ***p<0.001, **p<0.01, *p<0.05, rotenone-treated versus control rats 
 
 
6. Tissue contents of mitochondria and cytochromes 
Mitochondrial content was 24% decreased in striatum after 60 days of rotenone 
treatment (Table 6), in agreement with decreased tissue respiration and with impaired 
mitochondrial biogenesis, probably due to the time of rotenone treatment is about twice the 
time of brain mitochondrial turnover. The mitochondrial content in frontal cortex was not 
modified. Rotenone treatment did not affect cytochrome b and c contents in striatum and 

















mitochondria after 60 days of treatment while it remained unchanged in frontal cortex 
(Table 6).  
 
Table 6. Mitochondrial mass and cytochrome content in striatum and frontal cortex of 
rotenone-treated rats  
 
 Control Rotenone 
  30 days 60 days 
MITOCHONDRIAL CONTENT 
STRIATUM    
a Homogenate 908 ±  80 716 ± 72 534 ± 35* 
b Mitochondria 75 ± 8 61 ± 5   58 ± 5 
a/b Mitochondrial mass  12.1 ± 0.3 11.8 ± 0.3 9.2 ± 0.3*** 
FONTAL CORTEX    
a Homogenate 1364 ±  95 1187 ± 90 1042 ± 90 
b Mitochondria 101 ± 10 89 ± 9 82 ± 12 
a/b Mitochondrial mass  13.5 ± 0.4 13.3 ± 0.4 12.7 ± 0.3 
CYTOCHROME CONTENT    
STRIATUM    
Cytochromes c + c1 0.22 ± 0.02 0.19 ± 0.02 0.15 ± 0.02 
Cytochromes bK +bT 0.17 ± 0.02 0.17 ± 0.02 0.15 ± 0.02 
Cytochromes a + a3 0.16 ± 0.02 0.13 ± 0.02 0.11 ± 0.02 
FRONTAL CORTEX 
Cytochromes c + c1 0.19 ± 0.02 0.19 ± 0.02 0.19 ± 0.02 
Cytochromes bK +bT 0.18 ± 0.02 0.17 ± 0.02 0.16 ± 0.02 




















Rotenone is a high affinity stoichiometric inhibitor of mitochondrial complex I fitting in 
a crevice of complex I structure. In brain, heart and liver mitochondria full inhibitions are 
observed at 0.10 nmol rotenone/mg protein [23,50]. It has been described that the chronic 
intraperitoneal rotenone model is able to reproduce the two pathological hallmarks of PD, 
i.e. the degeneration of dopaminergic neurons in the substantia nigra and the presence of 
Lewy bodies in the surviving substantia nigra neurons as well as other regions of the 
central and peripheral nervous system, in addition to motor deficits, extranigral pathology 
and certain parkinsonian non-motor symptoms [36,38,39]. Moreover, it has been observed 
a good correlation between the chronic intraperitoneal rotenone-induced motor symptoms 
and the loss of tyrosine hydroxylase-positive neurons or dopamine depletion in the 
nigrostriatal pathway, as well as the non-motor symptoms and clinical state [51]. From the 
mitochondrial point of view, a complex I dysfunction has been reported in PD patients that 
to contribute to neurodegeneration [32,38,51,52]. Due to rotenone is able to penetrate all 
cells and mitochondria, chronic intraperitoneal rotenone model is useful to study the 
mitochondrial bioenergetics profile and for the understanding the brain mitochondrial 
impairments in human PD. Consequently, this in vivo model reproduces the inhibition of 
complex I by rotenone that has been observed in vitro, being this one of the 
pathognomonic characteristics of PD.  
In the present article, after 60 days of rotenone treatment, decreased striatum (34%) 
and frontal cortex (16%) state 3 malate-glutamate sustained respiration (Table 2) were 
observed. This impairment in mitochondrial O2 consumption was reflected in tissue 
respiration, since comparable O2 uptake declines, in rat striatum (35%) and frontal cortex 
(10%), were observed (Table 1). In sections of perfused tissues and organs, O2 
consumption rate depends is mainly accounted for the sum of the O2 uptakes of 
mitochondria respiring in state 3 and of mitochondria respiring in state 4. The decays in O2 

















Concerning respiratory complexes activities, only complex I activity was reduced in 
striatum and frontal cortex after 60 days of rotenone treatment (Table 3). These results are 
in agreement with those reported by Telford et al [53]. These authors have shown using 
metabolic control analysis that complex I is the component of the electron transfer chain 
which exerts a high level of control over synaptosomal bioenergetics. Consequently, 
complex I deficiencies, as for instance the one observed in neurodegenerative disorders, 
are sufficient to compromise O2 consumption. Striatum mitochondria showed not only 57% 
decreased complex I activity but also 60% decreased mtNOS activity (Table 3). Moreover, 
the functional activity of mtNOS, i.e. the inhibition of cytochrome oxidase and therefore O2 
uptake by endogenous NO, was markedly decreased after 60 days of rotenone treatment, 
with an intermediate value after 30 days of treatment (Table 4).  
Striatum and frontal cortex mitochondria showed increased production rates of O2
•- 
(34% and 41%) and H2O2 (40% and 44%), after 60 days of treatment (Table 5). To note, 
although the enhancement percentages in O2
•- and H2O2 productions in striatum are similar 
to the ones observed in frontal cortex, the net rate values of those productions are lower in 
this latter tissue. This fact is in agreement with the increases observed in phospholipid 
peroxidation and protein oxidation products in striatum (36% and 46%) and in frontal 
cortex (28% and 30%) (Table 5). In addition, considering also the mitochondrial respiratory 
dysfunction, in terms of state 3 O2 consumption sustained by malate-glutamate (Table 2) 
and complex I and mtNOS activities (Table 3), the “damage pattern” was lower in frontal 
cortex than in striatum, suggesting that frontal cortex mitochondria display a different 
response to changes in redox status, probably due to the antioxidant defences profile. It is 
important to consider that the degree of damage depends, among others, on O2
•- steady 
state concentration, i.e, not only on O2
•- production rate but also on O2
•- decomposition, 
which mainly occurs through SOD-dismutation reaction and the reaction between O2
•- and 
NO to yield ONOO-. Despite of the overall changes were more markedly in striatum than in 

















I syndrome [5], similar to the one observed in frontal cortex mitochondria from PD patients 
[54]. 
Dysfunction of complex I is usually accompanied by changes in mtNOS activity, 
increases in H2O2 and ONOO
- production rates and oxidative and/or nitrosative damage [5, 
11,12,18-21]. The decline in complex I and in mtNOS activities is consistent with the two 
enzymes structurally contiguous and functionally associated [10-13]. Poderoso's group 
[10] showed that not only complex IV but also complex I proteins immunoprecipitate with 
mtNOS, suggesting a molecular interaction among mtNOS and complexes I and IV. 
Furthermore, the functional association between complex I and mtNOS agrees with the 
observations by Parihar et al. [11] and our group [55] who sustained that mtNOS is 
structurally adjacent to complex I. Moreover, data from our laboratory [13] have shown that 
heart mitochondrial inside-out particles produce NO supported by succinate-dependent 
reversed electron flow in the respiratory chain, emphasizing the notion that mtNOS and 
complex I proteins are functionally associated and contiguously located. Therefore, 
changes in complex I structure (∼600 kDa) also affects adjacent mtNOS (130 kDa) 
conformation. It was speculated that the functional association between mtNOS and 
complex I is essential for preserving high rates of mitochondrial NO production and of 
mitochondrial biogenesis by the NO and cGMP dependent pathway [23,31]. The 
observations agree with the effects of rotenone in decreasing complex I activity and ATP 
levels with an over-expression of bcl-2 in striatum [56-57], and with complex I inhibition 
and increased phospholipid peroxidation in striatum bodies and frontal cortex [57].  
The development of complex I syndrome in rotenone treated rats is understood as a 
self-sustained process, started by rotenone binding with increased complex I auto-
oxidation and enhanced O2
•- production [12]. This sustains a free-radical mediated process 
including: (a) the Haber-Weiss chemistry of HO• production (eqs. 1-2) including the  
Fe3+(Cu2+)  +  O2
•-   →   Fe2+(Cu+)  +  O2    eq. 1 

















the Fenton reaction (eq. 2) [58,59]; (b) the lipid peroxidation chain reaction with the 
generation of the reactive peroxyl radical (ROO•); (c) the reactions of the lipid peroxidation 
produced aldehydes (4-hydroxynonenal and malonaldehyde) with the amino groups of 
complex I proteins; and (d) the nitration of complex I proteins by the increased formation of 
peroxynitrite (ONOO-), which is generated by the reaction of O2
•- and NO at the vicinity of 
complex I active center where O2
•- is produced and encounters the highly diffusive NO [60]. 
Generation of ONOO- seems to account for the main part of cell toxicity in rat brain. To 
note, even in physiopathological situations in which NO production is reduced, 
mitochondrial ONOO- production rate may be increased if the steady-state concentration of 
O2
•- is increased, with the consequent oxidation of biomolecules or modification of proteins 
by nitration, because mitochondrial ONOO- generation is mainly driven by O2
- steady-state 
concentration rather than by NO steady-state concentration [61]. Thus, these processes 
lead to complex I partial denaturalization, with polypeptide cross-linking, loss of native non-
covalent bonds and increased auto-oxidation rates. These facts have been proposed as 
the pathogenic mechanism for brain neurodegenerative diseases [17, 24, 46, 54, 62-64]. 
Interestingly, signaling from mitochondria seems to regulate cell metabolism and the 
expression of the nuclear-encoded components of the mitochondrial respiratory chain, a 
mechanism impaired in PD [63]. Indeed, immunoblotting of striatum mitochondria from PD 
patients showed that the expression levels of the 30-, 25- and 24-kDa subunits of complex 
I were moderately to markedly decreased [64]. In rat striatum, complex I syndrome was 
accompanied by a decreased tissue mitochondrial content (Table 6) that worsens the 
mitochondrial dysfunction. Dopaminergic neurons are more sensitive to rotenone 
poisoning than other brain cells; likely because they are subjected to a basal oxidative 
stress by a high endogenous O2
•- production in the autoxidation of catecholamines and 
dopamine. The reaction of NO and quinols produces semiquinones [65]. Interestingly, 
dopaminergic neurons in culture exposed to rotenone imitate some features of PD, 

















It has been observed that complex I syndrome is always associated with oxidative 
stress. The concept of oxidative stress was originally described as an unbalance between 
oxidant production and antioxidant defense [67,68] that was immediately accepted and 
successfully applied to organelles, cells, tissues and whole organisms. Jones and Sies 
extended the classical conception of oxidative stress to the “redox code” concept, where 
the increased oxidative reactions disrupt redox signaling and control, leading to cellular 
damage [69]. A high reduction of thiol groups (–SH) in GSH and in low molecular weight 
thiols is essential for keeping the intracellular reductive state that supports cell metabolism, 
signaling and regulation. 
There was an early recognition of increased lipid peroxidation [70] and of deficient 
complex I activity [52] in the substantia nigra of human PD patients. At present, both 
alterations are classic concepts of the biochemical alterations of dopaminergic neurons in 
PD. The present report shows that decreased mitochondrial NO production is another 
central alteration in PD. Microscopic examination of PD brains shows degeneration and 
death of dopaminergic neurons with Lewy bodies and α-synuclein in substantia nigra, 
medial temporal and limbic nuclei, and frontal cortex [32-33].   
It is clear that the complex I syndrome observed in striatum and frontal cortex in 
rotenone-treated rats corresponds to a situation of oxidative stress and damage with 
increased rates of harmful free-radical mediated reactions. These reactions and processes 
are likely to occur in human PD, affording a pathogenic mechanism. Thus, despite of its 
limitations, chronic intraperitoneal rotenone model may considered to be sufficiently similar 
to human disease and it is useful for the understanding of the brain mitochondrial 
impairments in PD, as well as to evaluate and select drug candidates that affect these 
processes to support their progression into clinical trials. For instance, it is likely that 
pharmacologic interventions as supplementation with exogenous antioxidants as vitamin E 
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• Striatum and cortex mitochondria of rotenone-treated rats exhibit “complex I 
syndrome”  
• Mitochondria show decreased O2  uptake -with NAD-dependent substrates- and NO 
production 
• Mitochondria show increased O2•-, H2O2, lipid peroxidation and protein oxidation 
• Rotenone-treated rats show decreased striatum mitochondrial mass  
• Mitochondrial complex I is highly sensitive to inactivation by oxidative reactions  
